Study of Early Calcium and Vasopressin Treatment in Trauma Patients at Risk of Severe Bleeding

What this Trial Is About

Researchers are evaluating the effectiveness and safety of early calcium and vasopressin treatment for patients at risk of hemorrhagic shock following traumatic injury. This phase 2, double-blind, multi-center trial focuses on improving resuscitation methods to reduce death and complications caused by severe blood loss. Despite advances in damage control resuscitation, deaths from traumatic hemorrhage remain high, highlighting the need for new early interventions. The study compares prehospital administration of 1 gram calcium gluconate given intravenously or intraosseously before hospital arrival with a saline placebo. In the early hospital phase, participants receive either a vasopressin bolus followed by an 8-hour infusion or a saline placebo infusion. These interventions aim to improve blood clotting, heart function, and blood pressure during trauma resuscitation. Patients may participate in either or both phases depending on their condition and timing. Participants undergo screening and then receive treatment while researchers monitor their health and outcomes. Assessments include survival rates up to 30 days, blood transfusion needs, organ failure, infections, blood clotting tests, and calcium levels. The study measures how these treatments affect mortality, complications, and recovery in trauma patients. Safety and efficacy data will be collected throughout the trial, which lasts up to four years.

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial